nach oben

Endocrine

Erschienen in:

01.06.2014 | Pros and Cons in Endocrine Practice

Cabergoline treatment in acromegaly: pros

verfasst von: Mónica Marazuela, Ana Ramos-Leví, Miguel Sampedro-Núñez, Ignacio Bernabeu

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Cabergoline is an ergot-derived dopamine D2 receptor agonist which may be effective for the medical management of acromegaly. Its efficacy in reducing growth hormone and IGF-I levels, as well as its antiproliferative and pro-apoptotic effects on pituitary tumor cells, has been observed in several studies. Cabergoline may be used alone or as an add-on therapy to patients who are partially resistant to somatostatin analogs (SSA), or who do not achieve complete control with maximum doses of pegvisomant (PEG). Additionally, the convenience of its oral administration, allowing better compliance, and its lower economic cost, in comparison with SSA and PEG, favor cabergoline as an attractive option for acromegalic patients, who frequently require long-life medical treatment to achieve disease control. The few adverse events observed with prolonged DA therapy, mainly regarding cardiac valve disease, are not frequent at the doses generally used in acromegaly.

A. Liuzzi, P.G. Chiodini, L. Botalla, G. Cremascoli, F. Silvestrini, Inhibitory effect of L-dopa on GH release in acromegalic patients. J. Clin. Endocrinol. Metab. 35, 941–943 (1972)PubMedCrossRef

R.B. Mims, R.B. Stein, J.E. Bethune, The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity, and in normal subjects. J. Clin. Endocrinol. Metab. 37, 34–39 (1973)PubMedCrossRef

M.O. Thorner, A. Chait, M. Aitken, G. Benker, S.R. Bloom, C.H. Mortimer, P. Sanders, A.S. Mason, G.M. Besser, Bromocriptine treatment of acromegaly. Br. Med. J. 1, 299–303 (1975)PubMedCentralPubMedCrossRef

J.A. Wass, M.O. Thorner, D.V. Morris, L.H. Rees, A.S. Mason, A.E. Jones, G.M. Besser, Long-term treatment of acromegaly with bromocriptine. Br. Med. J. 1, 875–878 (1977)PubMedCentralPubMedCrossRef

S. Melmed, Medical progress: acromegaly. N. Engl. J. Med. 14(355), 2558–2573 (2006)CrossRef

J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N. Engl. J. Med. 331, 904–909 (1994)PubMedCrossRef

B.M. Biller, A. Colao, S. Petersenn, V.S. Bonert, M. Boscaro, Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr. Disord. 10, 10 (2010)PubMedCentralPubMedCrossRef

J.J. An, S.R. Cho, D.W. Jeong, K.W. Park, Y.S. Ahn, J.H. Baik, Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol. Cell. Endocrinol. 206, 49–62 (2003)PubMedCrossRef

C. Ferrari, C. Barbieri, R. Caldara, M. Mucci, F. Codecasa, A. Paracchi, C. Romano, M. Boghen, A. Dubini, Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 63, 941–945 (1986)PubMedCrossRef

10.

C. Ferrari, A. Paracchi, C. Romano, G. Gerevini, M. Boghen, A. Barreca, P. Fortini, A. Dubini, Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. (Oxf.) 29, 467–476 (1988)CrossRef

11.

A. Colao, D. Ferone, P. Marzullo, A. Di Sarno, G. Cerbone, F. Sarnacchiaro, S. Cirillo, B. Merola, G. Lombardi, Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82, 518–523 (1997)PubMedCrossRef

12.

S.N. Jackson, J. Fowler, T.A. Howlett, Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (Oxf.) 46, 745–749 (1997)CrossRef

13.

R. Cozzi, R. Attanasio, M. Barausse, D. Dallabonzana, P. Orlandi, N. Da Re, V. Branca, G. Oppizzi, D. Gelli, Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur. J. Endocrinol. 139, 516–521 (1998)PubMedCrossRef

14.

R. Abs, J. Verhelst, D. Maiter, K. Van Acker, F. Nobels, J.L. Coolens, C. Mahler, A. Beckers, Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83, 374–378 (1998)PubMedCrossRef

15.

L. Vilar, M.A. Czepielewsk, L.A. Naves, G.A. Rollin, L.A. Casulari, C.E. Coelho, Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr. Pract. 13, 396–402 (2007)PubMedCrossRef

16.

V.J. Moyes, K.A. Metcalfe, W.M. Drake, Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur. J. Endocrinol. 159, 541–545 (2008)PubMedCrossRef

17.

P.U. Freda, C.M. Reyes, A.T. Nuruzzaman, R.E. Sundeen, A.G. Khandji, K.D. Post, Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7, 21–30 (2004)PubMedCrossRef

18.

L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)PubMedCrossRef

19.

M.R. Rickels, P.J. Snyder, Cabergoline decreases somatotroph adenoma size: a case report. Pituitary 7, 107–110 (2004)PubMedCrossRef

20.

J.A. Verhelst, P.J. Abrams, R. Abs, Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 11, 103–107 (2008)PubMedCrossRef

21.

P. Marzullo, D. Ferone, C. Di Somma, R. Pivonello, M. Filippella, G. Lombardi, A. Colao, Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1, 115–120 (1999)PubMedCrossRef

22.

R. Cozzi, R. Attanasio, S. Lodrini, G. Lasio, Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.) 61, 209–215 (2004)CrossRef

23.

B. Gatta, D.H. Hau, B. Catargi, P. Roger, A. Tabarin, Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin. Endocrinol. (Oxf.) 63, 477–478 (2005)CrossRef

24.

D. Selvarajah, J. Webster, R. Ross, J. Newell-Price, Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 152, 569–574 (2005)PubMedCrossRef

25.

R.S. Jallad, M.D. Bronstein, Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90, 82–92 (2009)PubMedCrossRef

26.

Vilchez R, Bernabeu I, Blanco C, Cordido F, Paja M, Casany R, Fajardo C, Maraver S, Martín T, Lucas T, García Arnes JA, Fernández Catalina P, Martínez de Icaya MP, Sesmilo G, Picó A, Marazuela M, Soto A, Puig Domingo M, on behalf of the ACROCOMB study group. Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly. The Endocrine Society’s 95th Annual Meeting & Expo 15–18 June 2013, San Francisco, CA, USA

27.

A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32, 247–271 (2011)PubMedCrossRef

28.

M. Sherlock, E. Fernandez-Rodriguez, A.A. Alonso, R.C. Reulen, J. Ayuk, R.N. Clayton, G. Holder, M.C. Sheppard, A. Bates, P.M. Stewart, Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J. Clin. Endocrinol. Metab. 94, 1255–1263 (2009)PubMedCrossRef

29.

M. Muratori, M. Arosio, G. Gambino, C. Romano, O. Biella, G. Faglia, Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. 20, 537–546 (1997)PubMedCrossRef

30.

J. Roemmler, B. Steffin, B. Gutt, H.J. Schneider, C. Sievers, M. Bidlingmaier, J. Schopohl, The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm. IGF Res. 20, 338–344 (2010)PubMedCrossRef

31.

P.J. Trainer, ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161(Suppl 1), S19–S24 (2009)PubMedCrossRef

32.

C.E. Higham, A.B. Atkinson, S. Aylwin, M. Bidlingmaier, W.M. Drake, A. Lewis, N.M. Martin, V. Moyes, J. Newell-Price, P.J. Trainer, Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J. Clin. Endocrinol. Metab. 97(4), 1187–1193 (2012)PubMedCrossRef

33.

I. Bernabeu, C. Alvarez-Escolá, A.E. Paniagua, T. Lucas, I. Pavón, J.M. Cabezas-Agrícola, F.F. Casanueva, M. Marazuela, Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16, 101–108 (2013)PubMedCrossRef

34.

M. Marazuela, T. Lucas, C. Alvarez-Escola, M. Puig-Domingo, N.G. de la Torre, P. de Miguel-Novoa, A. Duran-Hervada, R. Manzanares, M. Luque-Ramirez, I. Halperin, F.F. Casanueva, I. Bernabeu, Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur. J. Endocrinol. 160, 535–542 (2009)PubMedCrossRef

35.

R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med. 56, 39–46 (2007)CrossRef

36.

L. Maione, C. Garcia, A. Bouchachi, N. Kallel, P. Maison, S. Salenave, J. Young, P. Assayag, P. Chanson, No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97, E1714–E1719 (2012)PubMedCrossRef

37.

M. Kars, V. Delgado, E.R. Holman, R.A. Feelders, J.W. Smit, J.A. Romijn, J.J. Bax, A.M. Pereira, Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 93, 3348–3356 (2008)PubMedCrossRef

38.

S. Vallette, K. Serri, J. Rivera, P. Santagata, S. Delorme, N. Garfield, N. Kahtani, H. Beauregard, N. Aris-Jilwan, G. Houde, O. Serri, Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12, 153–157 (2009)PubMedCrossRef

39.

S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009)PubMedCrossRef

Titel: Cabergoline treatment in acromegaly: pros
verfasst von: Mónica Marazuela
Ana Ramos-Leví
Miguel Sampedro-Núñez
Ignacio Bernabeu
Publikationsdatum: 01.06.2014
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0206-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels

Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion

Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas

Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors

Erratum to: Thyroid nodules: team approach to a diagnostic and patient management challenge